Episode 817
TWiV 817: COVID-19 clinical update #84 with Dr. Daniel Griffin
October 16, 202145m 51s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #84, Dr. Griffin discusses childrens' antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.
Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Antibody profiles after mRNA vaccination in children (bioRxiv)
- Novavax vaccine phase 3 results (medRxiv)
- Heterologous vaccine boosters (medRxiv)
- Antithrombotic therapy outcomes (JAMA)
- Molnupiravir EUA submitted (Merck)
- AZD7442 phase 3 results (AstraZeneca)
- Serum ferritin levels and disease outcome (JAMA)
- Heparin efficacy (JAMA)
- WHO strategy to vaccinate world (WHO)
- Letters read on TWiV 817
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]